These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9848381)

  • 1. Malignant hyperthermia.
    Bouchama A; Hussain S
    Lancet; 1998 Nov; 352(9142):1785. PubMed ID: 9848381
    [No Abstract]   [Full Text] [Related]  

  • 2. Malignant hyperthermia and apparent heat stroke.
    Tobin JR; Jason DR; Challa VR; Nelson TE; Sambuughin N
    JAMA; 2001 Jul; 286(2):168-9. PubMed ID: 11448278
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification of variants of the ryanodine receptor type 1 in patients with exertional heat stroke and positive response to the malignant hyperthermia in vitro contracture test.
    Roux-Buisson N; Monnier N; Sagui E; Abriat A; Brosset C; Bendahan D; Kozak-Ribbens G; Gazzola S; Quesada JL; Foutrier-Morello C; Rendu J; Figarella-Branger D; Cozonne P; Aubert M; Bourdon L; Lunardi J; Fauré J
    Br J Anaesth; 2016 Apr; 116(4):566-8. PubMed ID: 26994242
    [No Abstract]   [Full Text] [Related]  

  • 4. Exertional Heat Stroke and Susceptibility to Malignant Hyperthermia in an Athlete: Evidence for a Link?
    Poussel M; Guerci P; Kaminsky P; Heymonet M; Roux-Buisson N; Faure J; Fronzaroli E; Chenuel B
    J Athl Train; 2015 Nov; 50(11):1212-4. PubMed ID: 26565425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central core disease and susceptibility to malignant hyperthermia in a single family.
    Colleoni L; Melli G; Morandi L; Cudia P; Romaggi S; Mantegazza R; Bernasconi P
    J Neurol; 2009 Jul; 256(7):1161-3. PubMed ID: 19252784
    [No Abstract]   [Full Text] [Related]  

  • 6. Malignant hyperthermia: a pharmacogenetic disorder.
    Stratman RC; Flynn JD; Hatton KW
    Orthopedics; 2009 Nov; 32(11):835. PubMed ID: 19902883
    [No Abstract]   [Full Text] [Related]  

  • 7. PharmGKB summary: very important pharmacogene information for RYR1.
    Alvarellos ML; Krauss RM; Wilke RA; Altman RB; Klein TE
    Pharmacogenet Genomics; 2016 Mar; 26(3):138-44. PubMed ID: 26709912
    [No Abstract]   [Full Text] [Related]  

  • 8. [Malignant hyperthermia as a complication of anesthesia: predisposition is hereditary].
    Snoeck MM; Gielen MJ; Sengers RC; Padberg GW; Iles DE; Booij LH
    Ned Tijdschr Geneeskd; 1997 Mar; 141(13):616-9. PubMed ID: 9190536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ryanodine on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
    Bina S; Muldoon S; Bünger R
    Eur J Anaesthesiol; 2008 Jan; 25(1):48-57. PubMed ID: 17686208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel mutation in the ryanodine receptor gene (RYR1) in a malignant hyperthermia Italian family.
    Fortunato G; Berruti R; Brancadoro V; Fattore M; Salvatore F; Carsana A
    Eur J Hum Genet; 2000 Feb; 8(2):149-52. PubMed ID: 10757649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of a family with the skeletal muscle RYR1 mutation (c.7354C>T) associated with central core myopathy and malignant hyperthermia susceptibility.
    Taylor A; Lachlan K; Manners RM; Lotery AJ
    J Clin Neurosci; 2012 Jan; 19(1):65-70. PubMed ID: 22030266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant hyperthermia: a pharmacogenetic disorder.
    Stowell KM
    Pharmacogenomics; 2008 Nov; 9(11):1657-72. PubMed ID: 19018722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA.
    Sato K; Pollock N; Stowell KM
    Anesthesiology; 2010 Jun; 112(6):1350-4. PubMed ID: 20461000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
    Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myopathic changes in malignant hyperthermia-susceptible patients.
    Rosenberg H
    Can J Anaesth; 2013 Oct; 60(10):955-9. PubMed ID: 23897489
    [No Abstract]   [Full Text] [Related]  

  • 16. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse.
    Chelu MG; Goonasekera SA; Durham WJ; Tang W; Lueck JD; Riehl J; Pessah IN; Zhang P; Bhattacharjee MB; Dirksen RT; Hamilton SL
    FASEB J; 2006 Feb; 20(2):329-30. PubMed ID: 16284304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
    Monnier N; Lunardi J
    Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genetics of malignant hyperthermia.
    Brandom BW
    Anesthesiol Clin North Am; 2005 Dec; 23(4):615-9, viii. PubMed ID: 16310654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Core myopathies and risk of malignant hyperthermia.
    Klingler W; Rueffert H; Lehmann-Horn F; Girard T; Hopkins PM
    Anesth Analg; 2009 Oct; 109(4):1167-73. PubMed ID: 19762745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.